Search results
Results from the WOW.Com Content Network
People sometimes use cannabis to cope with their anxiety, and cannabis withdrawal can lead to symptoms of anxiety. [58] Buspirone, a serotonin 5-HT 1A receptor partial agonist, has shown limited efficacy for treating anxiety in people with cannabis use disorder, though there may be better efficacy in males than in females. [58]
“Initiating cannabis at a younger age is a risk factor for developing problematic cannabis use, which can involve cravings, tolerance, withdrawal, difficulty cutting down on use, issues ...
Still, studies do exist, such as one in the journal Depression and Anxiety that notes that easing anxiety is among the top five symptoms for which people in North America use medical marijuana.
Legal cannabis (marijuana) product. Overconsumption and reliance could lead to cannabis-induced amotivational syndrome. The term amotivational syndrome was first devised to understand and explain the diminished drive and desire to work or compete among the population of youth who are frequent consumers of cannabis and has since been researched through various methodological studies with this ...
For sexual minority women, have indicated higher cannabis use, coping motives, and post-traumatic stress symptoms than heterosexual women. [16] [17] This may suggest that for women, trauma symptoms may be more severe for those who belong to a minority status, and the necessity to cope is often met by increasing cannabis use. These findings ...
In one study, cannabis use was associated with an increased risk of psychotic symptoms during manic episodes. Another review found a link between cannabis use and an increased risk of developing ...
Withdrawal management is the medical and psychological care of patients who are experiencing withdrawal symptoms due to the ceasing of drug use. [48] Depending on the severity of use, and the given substance, early treatment of acute withdrawal may include medical detoxification .
Withdrawal: Upon cessation of the behavior or the drug effect wearing off, individuals experience negative mood states, including anxiety and anhedonia, due to the dampened reward system. Withdrawal processes are mediated by basal forebrain areas and neurotransmitters such as corticotropin-releasing factor (CRF) and norepinephrine.